Gene Therapy for Mucopolysaccharidosis Type II-A Review of the Current Possibilities

Area of Science:

• Biochemistry
• Genetics
• Medical Research

Background:

• Mucopolysaccharidosis type II (MPS II) is a genetic lysosomal storage disorder caused by mutations in the IDS gene, leading to glycosaminoglycan accumulation.
• This accumulation results in widespread tissue dysfunction and is primarily managed with enzyme replacement therapy (ERT).
• ERT effectively treats somatic symptoms but fails to cross the blood-brain barrier, leaving central nervous system manifestations unaddressed, particularly in severe MPS II cases.

Purpose of the Study:

• To review the history and fundamental principles of gene therapy.
• To discuss the current advancements and methodologies of gene therapy applications for MPS II.
• To highlight gene therapy as a potential solution for the limitations of ERT in MPS II treatment.

Main Methods:

• Review of existing literature on gene therapy for MPS II.
• Analysis of progress from cellular models to human clinical trials.
• Discussion of vector-based gene delivery strategies.

Main Results:

• Significant progress has been made in developing gene therapy for MPS II.
• Gene therapy approaches are being evaluated in human clinical trials.
• The potential for gene therapy to address CNS symptoms in MPS II is being explored.

Conclusions:

• Gene therapy represents a viable alternative to ERT for MPS II, particularly for addressing neurological deficits.
• Ongoing research and clinical trials are crucial for realizing the full therapeutic potential of gene therapy in MPS II.
• Further development is needed to optimize gene delivery and efficacy for long-term treatment outcomes.